Browse Categories
Search
Stay In Touch
Login
|
|
Home > All Products > Top 200 Drugs A Five-Year Compilation updated with 2010 data
Top 200 Drugs A Five-Year Compilation updated with 2010 data
|
Item Number: DRTZ501
Purchase the Reference Guide to the Top 200 Pharmaceutical Drugs titled “Top 200 Drugs: A 5-Year Compilation” for $59.95 online at IndustryMatter.com.
Learn where top selling drugs such as Lipitor, Nexium, Norvasc, Remicade, and Singulair rank by total prescriptions and retail dollar.
This reference manual to the top selling pharmaceutical medications is an essential resource for pharmacology professionals, pharmacists, physicians, health care practice managers, pharmaceutical executives, pharmaceutical representatives, managed healthcare executives, nurse practitioners, physician assistants and medical students.
This reference guide is compiled from information developed by Drug Topics magazine, which specializes in pharmacy & clinical news for pharmacists. The monthly news magazine is guided by a board of pharmacy leaders, reporting on all phases of community, retail, and health-system issues and trends. They cover managed care and professional, national, and state activities as well as new therapies involving prescription and OTC drugs.
Drug Topics has updated this year-over-year comparison of the Top 200 Drugs to include 2010 data in the following categories:
-
Brand-name Drugs by Total Prescriptions 2006-2010
-
Brand-name Drugs by Retail Dollar 2006-2010
-
Generic Drugs by Total Prescriptions 2006-2010
-
Generic Drugs by Retail Dollar 2006-2010
A handy desk-top reference guide you can refer to again and again.
In addition to the valuable comparisons you will also receive the following additional Bonus Material:
-
Pipeline Drugs 2011
-
Major brand-name drugs face patent expiration
-
REMS update: Solutions for REMS implementation in hospital and retail settings
-
Effective Rx choices depend on careful literature review
-
Biogenerics savings may be slow to materialize
-
Compounded drugs give indies the edge
-
Drug prices can't depend on who's buying
-
Hospital drug expenditures continue to rise
-
Herbal supplements are hot sellers
-
Off-label prescriptions in certain classes lack evidence
-
RX drugs are losing to generics in war for consumer dollars
|
|
|
|